Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 11, 2022, announces preliminary financial and operational results for Pulse Biosciences, Inc. for the fiscal quarter and full year ended December 31, 2021. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol PLSE.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not detailed in the body of this 8-K. The financial information is unaudited and subject to adjustment in the final audited statements.
Material Changes
No specific material changes versus prior periods are quantified in this filing. The report serves as a notification that preliminary results have been announced and directs investors to the press release for details.
Guidance, Outlook, and Management Commentary
- Earnings Call: The company expects to report complete 2021 financial results on its fourth-quarter and full-year earnings call, scheduled to be held later in the first quarter of 2022.
- Status of Data: The preliminary results are unaudited and subject to adjustment in the final audited financial statements to be filed in the Annual Report on Form 10-K.
- Legal Status: The information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, net loss, and cash position figures.
- Verify the date and time of the upcoming fourth-quarter and full-year earnings call.
- Monitor the subsequent Form 10-K filing for audited financial statements and potential adjustments to the preliminary numbers.
- Confirm the company's status as an emerging growth company and any related accounting election impacts.